Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2

Update Il y a 4 ans
Reference: EUCTR2015-003385-84

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement


Inclusion criteria

  • Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1,
  • or ALK Gene Rearrangements